Jefferies Sticks to Their Hold Rating for Aurinia Pharmaceuticals (AUPH)
Jefferies analyst Maury Raycroft reiterated a Hold rating on Aurinia Pharmaceuticals today and set a price target of $10.00. The company’s shares closed yesterday at $11.06.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Raycroft covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Travere Therapeutics, and Aurinia Pharmaceuticals. According to TipRanks, Raycroft has an average return of 9.1% and a 41.37% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aurinia Pharmaceuticals with a $11.67 average price target.
The company has a one-year high of $13.44 and a one-year low of $6.55. Currently, Aurinia Pharmaceuticals has an average volume of 2.08M.
Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is neutral on the stock. Last month, Greg Keenan, the CMO of AUPH sold 20,000.00 shares for a total of $210,000.00.
Read More on AUPH:
Disclaimer & DisclosureReport an Issue
- Aurinia Pharmaceuticals Reaffirms Confidence in LUPKYNIS After Retraction
- Aurinia drops after FDA official criticizes voclosporin
- Promising Drug Pipeline and Positive Trial Results Drive Buy Rating for Aurinia Pharmaceuticals
- Aurinia Pharmaceuticals: Strong Financial Performance and Promising Pipeline Drive Buy Rating
- Aurinia Pharmaceuticals: Strong Financial Performance and Promising Future Justify Buy Rating
